GENinCode (LON:GENI) Trading Down 5.3% – Here’s Why

Shares of GENinCode Plc (LON:GENI) were down 5.3% during trading on Tuesday . The company traded as low as GBX 0.85 and last traded at GBX 0.90. Approximately 11,692,215 shares traded hands during mid-day trading, an increase of 84% from the average daily volume of 6,365,636 shares. The stock had previously closed at GBX 0.95.

GENinCode Price Performance

The business’s 50 day moving average price is GBX 1.12 and its 200 day moving average price is GBX 1.50. The stock has a market capitalization of £6.53 million, a P/E ratio of -0.38 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a current ratio of 0.93 and a quick ratio of 15.89.

GENinCode (LON:GENI) last announced its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The company had revenue of GBX 308 million during the quarter. Sell-side analysts forecast that GENinCode Plc will post -7.1299999 EPS for the current year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.